Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Primary result · Kidney disease progressionResult — go to the resultHazard ratio 0.71 95% CI 0.62–0.81Authors' conclusion
In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease.
Study context
- Population
- Patients with CKD and estimated glomerular filtration rate (eGFR) 20 to <45 mL/min per 1.73 m², or 45 to <90 mL/min per 1.73 m² with urinary albumin-to-creatinine ratio (uACR) ≥200 mg/g; subgroups: diabetic kidney disease 2057 (31.1%), glomerular disease 1669 (25.3%), hypertensive or renovascular disease 1445 (21.9%), other or unknown causes 1438 (21.8%)randomised 1:1
- Participants
- 6,609 patients
- Comparison
- Empagliflozin 10 mg once daily vs placebo, by primary kidney disease
- Empagliflozinn = 3,304
- Placebon = 3,305reference
Methodological detailscontrolled, phase 3, prespecified subgroups, 241 centres in eight countries
- Controlled
- Phase 3
- Prespecified subgroups
- 241 centres in eight countries
Primary result
Kidney disease progression
Hazard ratio
0.71
95% CI 0.62–0.81
P = 0.62 for heterogeneity
Events by treatment group
As reported in the abstract
Further findings
| Outcome | Between-group difference (mL/min per 1.73 m² per year) (95% CI) | |
|---|---|---|
| Chronic eGFR slope (2 months to final follow-up) | 1.37 (1.16–1.59) | |
| −1012Difference, mL/min per 1.73 m² per year (linear scale) |
- Chronic eGFR slope (2 months to final follow-up) — Reduction in rate of chronic eGFR decline
- 50% (42-58)
- Chronic eGFR slope (2 months to final follow-up) — Relative effect on chronic eGFR slope similar by primary kidney disease, type of glomerular disease and diabetes
- p values for heterogeneity all >0.1
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →